GUIDANCE DOCUMENT
Dry Eye: Developing Drugs for Treatment Guidance for Industry December 2020
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-2020-D-2214
- Issued by:
-
Guidance Issuing OfficeCenter for Drug Evaluation and Research
Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.
For questions regarding this draft document, contact Wiley Chambers at 301-796-0690.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2020-D-2214.